<DOC>
	<DOCNO>NCT02725476</DOCNO>
	<brief_summary>The purpose Phase 2 study investigate effect XmAb5871 IgG4-Related Disease ( RD ) activity</brief_summary>
	<brief_title>Study Evaluate Effect XmAb®5871 Disease Activity Patients With IgG4-Related Disease ( RD )</brief_title>
	<detailed_description />
	<criteria>Active IgG4RD Compatible pattern organ involvement consistent IgG4RD attribute cause Histopathologicallyproven diagnosis IgG4RD Peripheral blood plasmablast count &gt; 900 cells/mL and/or elevate IgG4RD level screen Able willing complete entire study accord study schedule Able willing provide write informed consent History evidence clinically unstable/uncontrolled disorder , condition disease IgG4RD , opinion Investigator would pose risk patient safety interfere study evaluation , procedures completion Malignancy within 5 year ( except successfully treat situ cervical cancer , resect squamous cell basal cell carcinoma skin , prostate cancer recurrence ≥3 year follow prostatectomy ) Presence recurrent chronic infection , define ≥3 infection require antimicrobial past 6 month prior screen Active infection require hospitalization treatment parenteral antimicrobial within 60 day prior randomization oral antimicrobial within 21 day prior enrollment Patient take &gt; 40 mg prednisone QD Prior use rituximab ( B cell deplete agent ) within 6 month enrollment . Prior use B cell deplete agent great 6 month enrollment allow CD19+ B cell count within normal reference range screen Use investigational agent within 5 halflives agent ( 6 month halflife unknown ) prior enrollment Immunosuppressive agent use within three month prior enrollment Has receive live vaccine within 2 month enrollment Patient pregnant breast feeding , plan become pregnant enrolled study , endofstudy visit Unable unwilling partake followup assessment require protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>